Abstract
The administration of abciximab during primary percutaneous coronary intervention reduces the risks for death and recurrent MI at 30 days (Journal
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have